Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities

<p>They walk us through the history of bispecifics, which have been talked about since the early 2000&#39;s, and the use cases for them today. Plus, a deep dive into the science, which includes discussing your body&#39;s reaction to then, affinity &amp; avidity, CMC, and &#39;bead-on-a-string&#39; approaches that some have used lately. Finally, a discussion of what the future holds.</p>